Skip to content

Use of transvaginal non-ablative Radiofrequency in the Treatment of Urinary Incontinence and Vaginal Atrophy

Transvaginal non-ablative Radiofrequency in the Treatment of Urinary Incontinence and Genitourinary Syndrome of Menopause: blinded, controlled, randomized clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-6g8mjzk
Enrollment
Unknown
Registered
2023-08-08
Start date
2019-09-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genitourinary Syndrome of Menopause. Urinary incontinence

Interventions

This is a randomized, controlled clinical trial, blinded to study participants. The Randomization was defined by using the method of randomly permuted blocks at randomization.com. The sample size is 6

Sponsors

Universidade de Caxias do Sul - UCS
Lead Sponsor
Universidade de Caxias do Sul - UCS
Collaborator

Eligibility

Sex/Gender
Female
Age
45 Years to No maximum

Inclusion criteria

Inclusion criteria: Postmenopausal women, diagnosed with genitourinary syndrome of menopause, urinary incontinence (stress or mixed with predominance of stress)

Exclusion criteria

Exclusion criteria: Expressed desire for surgical treatment for urinary incontinence; identification of the presence of pelvic tumors; grade III and IV pelvic prolapse; previous surgery for urinary incontinence or genital prolapse; neurogenic bladder; cardiac pacemaker carriers; being under physical therapy treatment for urinary incontinence; have a urinary tract infection in a previously performed urine test

Design outcomes

Primary

MeasureTime frame
We expect to find an improvement in the symptoms of the menopausal genitourinary syndrome using transvaginal non-ablative radiofrequency in the treatment of the menopausal genitourinary syndrome, through the application of specific and validated questionnaires for quality of life and sexual satisfaction, as well as the evaluation of vaginal pH, estimating a 5-point improvement between the pre and post-treatment evaluations Translated with www.DeepL.com/Translator (free version)

Secondary

MeasureTime frame
Describe safety and possible side effects induced by Radiofrequency non ablative transvaginal

Countries

Brazil

Contacts

Public ContactHaley Dos Santos

Universidade de Caxias do Sul - UCS

hcalcagnotto@yahoo.com.br+5554999394340

Outcome results

None listed

Source: REBEC (via WHO ICTRP)